{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IGI%2C+10%25",
    "query": {
      "intervention": "IGI, 10%"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 6,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-20T01:47:52.048Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02955355",
      "title": "Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Inflammatory Demyelinating Polyradiculoneuropathy"
      ],
      "interventions": [
        {
          "name": "HYQVIA",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2016-11-14",
      "completion_date": "2023-07-04",
      "has_results": true,
      "last_update_posted_date": "2024-08-28",
      "last_synced_at": "2026-09-20T01:47:52.048Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02955355"
    },
    {
      "nct_id": "NCT06980480",
      "title": "A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Secondary Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "IGI, 10%",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 183,
      "start_date": "2026-01-14",
      "completion_date": "2028-09-11",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-09-20T01:47:52.048Z",
      "location_count": 7,
      "location_summary": "Mobile, Alabama • Orange, California • Westwood, Kansas + 4 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06980480"
    },
    {
      "nct_id": "NCT03277313",
      "title": "Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immunodeficiency Diseases (PID)"
      ],
      "interventions": [
        {
          "name": "HYQVIA",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "15 Years",
        "sex": "ALL",
        "summary": "2 Years to 15 Years"
      },
      "enrollment_count": 44,
      "start_date": "2017-09-25",
      "completion_date": "2022-07-20",
      "has_results": true,
      "last_update_posted_date": "2023-10-23",
      "last_synced_at": "2026-09-20T01:47:52.048Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Hartford, Connecticut • Miami, Florida + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Albany",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03277313"
    },
    {
      "nct_id": "NCT02549170",
      "title": "A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Inflammatory Demyelinating Polyradiculoneuropathy"
      ],
      "interventions": [
        {
          "name": "HYQVIA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "0.25% albumin placebo solution with rHuPH20",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IGIV GAMMAGARD LIQUID/KIOVIG",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IGIV GAMUNEX®-C",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 138,
      "start_date": "2015-12-15",
      "completion_date": "2022-02-23",
      "has_results": true,
      "last_update_posted_date": "2023-05-24",
      "last_synced_at": "2026-09-20T01:47:52.048Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Orange, California + 14 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02549170"
    },
    {
      "nct_id": "NCT01485796",
      "title": "Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Primary Immunodeficiency Diseases (PID)"
      ],
      "interventions": [
        {
          "name": "Immune Globulin Infusion (Human), 10%",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant human hyaluronidase",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2011-12-29",
      "completion_date": "2013-01-01",
      "has_results": true,
      "last_update_posted_date": "2021-05-19",
      "last_synced_at": "2026-09-20T01:47:52.048Z",
      "location_count": 10,
      "location_summary": "Irvine, California • Thornton, Colorado • North Palm Beach, Florida + 7 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Thornton",
          "state": "Colorado"
        },
        {
          "city": "North Palm Beach",
          "state": "Florida"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Plymouth",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01485796"
    },
    {
      "nct_id": "NCT04578535",
      "title": "A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "HYQVIA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "19 Years to 50 Years"
      },
      "enrollment_count": 51,
      "start_date": "2020-10-27",
      "completion_date": "2022-03-02",
      "has_results": true,
      "last_update_posted_date": "2023-12-14",
      "last_synced_at": "2026-09-20T01:47:52.048Z",
      "location_count": 1,
      "location_summary": "Hialeah, Florida",
      "locations": [
        {
          "city": "Hialeah",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04578535"
    }
  ]
}